CoChat

Systemic immune-inflammation index predicting chemoradiation resistance and poor outcome in patients with stage III non-small cell lung cancer

Open access
Tong, Yu-Suo, Tan, Juan, Zhou, Xi-Lei, Song, Ya-Qi, Song, Ying-Jian · 2017 · Journal of Translational Medicine

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Abstract

There is increasing evidence that the existence of systemic inflammation response is correlated with poor prognosis in several solid tumors. The aim of this retrospective study was to investigate the association between systemic immune-inflammation index (SII) and therapy response and overall survival in patients with stage III non-small cell lung cancer (NSCLC). The prognostic values of neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), and prognostic nutritional index (PNI) were also evaluated. In total, 332 patients with new diagnosis of stage III NSCLC were included in this retrospective analysis. SII was defined as platelet counts × neutrophil counts/lymphocyte counts. Receiver operating characteristic (ROC) curve was used to evaluate the optimal cut-off value for SII, NLR, PLR and PNI. Univariate and multivariate survival analysis were performed to identify the factors correlated with overall survival. Applying cut-offs of ≥ 660 (SII), ≥ 3.57 (NLR), ≥ 147 (PLR), ≤ 52.95 (PNI), SII ≥ 660 was significantly correlated with worse ECOG PS (< 0.001), higher T stage (< 0.001), advanced clinical stage (p = 0.019), and lower response rate (p = 0.018). In univariate analysis, SII ≥ 660, NLR ≥ 3.57, PLR ≥ 147, and PNI ≤ 52.95 were significantly associated with worse overall survival (p all < 0.001). Patients with SII ≥ 660 had a median overall survival of 10 months, and patients with SII < 660 showed a median overall survival of 30 months. In multivariate analysis only ECOG PS (HR, 1.744; 95% CI 1.158–2.626; p = 0.008), T stage (HR, 1.332; 95% CI 1.032–1.718; p = 0.028), N stage (HR, 1.848; 95% CI 1.113–3.068; p = 0.018), SII (HR, 2.105; 95% CI 1.481–2.741; p < 0.001) and NLR ≥ 3.57 (HR, 1.934; 95% CI 1.448–2.585; p < 0.001) were independently correlated with overall survival. This study demonstrates that the SII is an independent prognostic indicator of poor outcomes for patients with stage III NSCLC and is superior to other inflammation-based factors in terms of prognostic ability.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12967-017-1326-1

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Receiver operating characteristic curve analysis for the optimal cut-off value of SII, NLR, PLR and PNI. The areas under the curve for overall survival were 0.673, 0.603, 0.604 and 0.621 for SII, NLR, PLR and PNI, respectively
Fig. 1 Receiver operating characteristic curve analysis for the optimal cut-off value of SII, NLR, PLR and PNI. The areas under the curve for overall survival were 0.673, 0.603, 0.604 and 0.621 for SII, NLR, PLR and PNI, respectivelyCC BY · PubMed Central
Fig. 2 Kaplan–Meier curves of overall survival according to SII (a), NLR (b), PLR (c) and PNI (d)
Fig. 2 Kaplan–Meier curves of overall survival according to SII (a), NLR (b), PLR (c) and PNI (d)CC BY · PubMed Central
Fig. 3 Kaplan–Meier survival analysis in stage III A (a) and stage III B (b) NSCLC subgroup
Fig. 3 Kaplan–Meier survival analysis in stage III A (a) and stage III B (b) NSCLC subgroupCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 37 references

Cited by

See all 244

Metadata

Authors
Tong, Y.-S., Tan, J., Zhou, X.-L., Song, Y.-Q., & Song, Y.-J.
Affiliations
Huaian First People’s Hospital (CN)
Venue
Journal of Translational Medicine
Published
2017-10-31
Volume
15
Issue
1
Pages
221-221
ISSN
1479-5876 (ISSN-L)
OpenAlex
W2767077750
Cited by
233
References
37
Citations by year
2026: 19 · 2025: 26 · 2024: 38 · 2023: 29 · 2022: 27 · 2021: 35 · 2020: 26 · 2019: 21 · 2018: 12
FWCI
7.11
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Journal of Translational Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Natural Science Foundation of China
Topics
  • Health Sciences › Medicine › Oncology › Inflammatory Biomarkers in Disease Prognosis
  • Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Keywords
systemic immune-inflammation index, non-small cell lung cancer, stage III NSCLC, systemic inflammation, chemoradiotherapy resistance, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, prognostic nutritional index, overall survival, prognostic factors, treatment response, ECOG performance status, T stage, N stage, prognostic cutoff values
MeSH terms
Adult, Aged, Carcinoma, Non-Small-Cell Lung, Female, Humans, Inflammation, Lung Neoplasms, Male, Middle Aged, Neoplasm Staging, Neutrophils, Platelet Count, ROC Curve, Nutrition Assessment, Multivariate Analysis, Treatment Outcome, Lymphocyte Count, Kaplan-Meier Estimate, Chemoradiotherapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Systemic immune-inflammation index predicting chemoradiation resistance and poor outcome in patients with stage III non-small cell lung cancer. https://app.cochat.ai/papers/10.1186/s12967-017-1326-1
The paper
Tong, Y.-S., Tan, J., Zhou, X.-L., Song, Y.-Q., & Song, Y.-J. (2017). Systemic immune-inflammation index predicting chemoradiation resistance and poor outcome in patients with stage III non-small cell lung cancer. Journal of Translational Medicine. https://doi.org/10.1186/s12967-017-1326-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.